View article

We investigated the efficacy and toxicity of the etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx), in which oxaliplatin (Ox) was substituted for cisplatin in the ESHAP [etoposide (E), methylprednisolone (S), high-dose cytarabine (HA), and cisplatin (P)] regimen, for patients with refractory/relapsed aggressive non-Hodgkin’s lymphoma (NHL).

The ESHAOx consisted of E (40 mg/m² on days 1–4), S (500 mg on days 1–5), HA (2 g/m² on day 5), and Ox (130 mg/m² on day 1) every 3 weeks to a maximum of six cycles. Responses were assessed every three cycles.

Twenty-seven patients were enrolled (19 with relapsed and 8 with refractory; 10 with an IPI score of 3–5). The overall response rate was 63% [95% confidence interval (95% CI) 45–81 …